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BACKGROUND
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free 
and overall survival than ipilimumab alone in a trial involving patients with ad-
vanced melanoma. We now report 5-year outcomes in the trial.
METHODS
We randomly assigned patients with previously untreated advanced melanoma to 
receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram 
of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, 
followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per 
kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg 
per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo. The 
two primary end points were progression-free survival and overall survival in the 
nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with 
the ipilimumab group.
RESULTS
At a minimum follow-up of 60 months, the median overall survival was more than 
60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 
months in the nivolumab group, as compared with 19.9 months in the ipilimumab 
group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 
0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall sur-
vival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the 
nivolumab group, as compared with 26% in the ipilimumab group. No sustained 
deterioration of health-related quality of life was observed during or after treat-
ment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic 
effects were noted.
CONCLUSIONS
Among patients with advanced melanoma, sustained long-term overall survival at 
5 years was observed in a greater percentage of patients who received nivolumab 
plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, 
with no apparent loss of quality of life in the patients who received regimens con-
taining nivolumab. (Funded by Bristol-Myers Squibb and others; CheckMate 067 
ClinicalTrials.gov number, NCT01844505.)
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I n the past decade, progress in the treatment of advanced melanoma has mark-edly improved survival outcomes.1 The avail-
ability of new systemic therapies — including 
ipilimumab, an anti–cytotoxic T-lymphocyte–
associated antigen 4 monoclonal antibody; anti–
programmed death 1 agents (nivolumab and 
pembrolizumab); nivolumab in combination 
with ipilimumab; and BRAF and MEK inhibitors 
(dabrafenib plus trametinib, vemurafenib plus 
cobimetinib, and encorafenib plus binimeti-
nib)— has transformed the treatment of this 
disease.1
Initial and follow-up analyses of the phase 3 
CheckMate 067 trial, including analyses across 
clinically relevant subgroups, showed a signifi-
cantly higher response rate and longer progression-
free survival and overall survival with nivolumab 
plus ipilimumab or nivolumab alone than with 
ipilimumab alone among patients with advanced 
melanoma.2-4 Combination therapy with nivolu-
mab plus ipilimumab has also had clinical effi-
cacy in patients with metastatic melanoma and 
untreated brain metastases.5,6 Some patients who 
have received nivolumab plus ipilimumab have 
also discontinued therapy without subsequent 
systemic treatment for melanoma4,7-9; this is one 
aspect of the value of combination nivolumab 
plus ipilimumab treatment. In this article, we 
provide an update of survival outcomes from the 
CheckMate 067 trial with a minimum of 5 years 
of follow-up as well as an assessment of the long-
term benefit of combination nivolumab plus ipilim-
umab treatment with respect to outcomes in 
patients who have not received subsequent sys-
temic treatment for melanoma and with respect 
to health-related quality of life.
Me thods
Patients
Adult patients with previously untreated, unre-
sectable or metastatic histologically confirmed 
stage III or stage IV melanoma, with known BRAF 
V600 mutation status, and with an Eastern Coop-
erative Oncology Group performance-status score 
of 0 or 1 (on a 5-point scale, with higher scores 
indicating greater disability) were included in the 
trial. The full trial eligibility criteria, design, and 
assessments have been reported previously.4
Trial Design and Treatment
Patients were randomly assigned in a 1:1:1 ratio 
to receive one of the following regimens: 
nivolumab at a dose of 1 mg per kilogram of 
body weight every 3 weeks plus ipilimumab at a 
dose of 3 mg per kilogram every 3 weeks for 
four doses, followed by nivolumab at a dose of 
3 mg per kilogram every 2 weeks; nivolumab at 
a dose of 3 mg per kilogram every 2 weeks (plus 
ipilimumab-matched placebo); or ipilimumab at 
a dose of 3 mg per kilogram every 3 weeks for 
four doses (plus nivolumab-matched placebo). 
Randomization was stratified according to BRAF 
mutation status, metastasis stage defined accord-
ing to the American Joint Committee on Cancer, 
and tumor programmed cell death ligand 1 
(PD-L1) status.
Treatment was continued until disease pro-
gression, the occurrence of unacceptable toxic 
events, or withdrawal of consent. Patients with 
clinical benefit and without substantial adverse 
events could be treated beyond progression ac-
cording to the investigator’s decision. Minimum 
follow-up was defined as the time from the date 
on which the last patient underwent randomiza-
tion to the clinical cutoff date; the extent of fol-
low-up (for which the median is reported) was 
defined as the time between the randomization 
date and the last known date alive (for patients 
who were alive) or death date (for patients who 
had died).
The two primary end points were progression-
free survival and overall survival, as compared be-
tween the nivolumab-plus-ipilimumab group or the 
nivolumab group and the ipilimumab group. Sec-
ondary end points included a comparison of the 
objective response rate between the nivolumab-
containing groups and the ipilimumab group 
and descriptive efficacy evaluations between the 
nivolumab-plus-ipilimumab group and the nivol u-
mab group. Additional analyses (survival end points 
according to subgroup and evaluations of the 
treatment-free interval and treatment-free status) 
have been published previously3,4 and are detailed 
in the Supplementary Methods section in the Sup-
plementary Appendix, available with the full text of 
this article at NEJM.org. Evaluations of health-
related quality of life as determined on the basis 
of the mean change from baseline analyses with 
the use of the European Quality of Life 5-Dimen-
n engl j med 381;16 nejm.org October 17, 2019 1537
Survival with Nivolumab and Ipilimumab in Melanoma
sions 3-Level (EQ-5D-3L) questionnaire10,11 are de-
tailed in the Supplementary Methods section.
Trial Oversight
The protocol and amendments for this trial (avail-
able at NEJM.org) were reviewed by the institu-
tional review board at each trial site. The trial 
was conducted in accordance with the Declara-
tion of Helsinki and with Good Clinical Prac-
tice guidelines as defined by the International 
Conference on Harmonisation. All the patients 
provided written informed consent before en-
rollment.
The trial was designed by the senior aca-
demic authors and the sponsor, Bristol-Myers 
Squibb. Data were collected by the sponsor and 
analyzed in collaboration with the authors. The 
authors vouch for the accuracy and complete-
ness of the data reported and also confirm ad-
herence to the protocol. The initial manuscript 
was written in collaboration with the first au-
thor and the last two authors, who provided di-
rect input into all key sections. All the authors 
contributed to subsequent drafts and provided 
final approval to submit the manuscript for 
publication. Professional medical writing and 
editorial assistance were paid for by the sponsor. 
A data and safety monitoring committee pro-
vided oversight to assess the risk–benefit profile 
of nivolumab plus ipilimumab, as described pre-
viously.2,3
Statistical Analysis
Efficacy end points were based on the intention-
to-treat population. Formal analyses of the two 
primary end points were conducted at different 
prespecified time points according to the trial 
protocol, as described previously.2,3 A 60-month 
follow-up to assess overall survival, progression-
free survival, and the objective response rate 
with confidence intervals at the 95% level was 
performed, and updated P values were provided 
for descriptive purposes. The trial was not de-
signed for a formal statistical comparison between 
the nivolumab-plus-ipilimumab group and the 
nivolumab group, but descriptive analyses with-
out formal hypothesis testing were performed. 
Details of the statistical analysis are provided in 
the Supplementary Methods section and have been 
published previously.2-4
R esult s
Patients and Treatment
From July 2013 through March 2014, a total of 
1296 patients were enrolled and 945 underwent 
randomization (314 to the nivolumab-plus-ipilim-
umab group, 316 to the nivolumab group, and 
315 to the ipilimumab group) (Fig. S1). The 
baseline characteristics of the patients have 
been reported previously (Table S1),2-4 and in-
formation on drug exposure is provided in Ta-
ble S2.
At database lock on July 2, 2019, the mini-
mum follow-up from the date on which the last 
patient underwent randomization was 60 months. 
The median extent of follow-up was 54.6, 36.0, 
and 18.6 months for the nivolumab-plus-ipilim-
umab, nivolumab, and ipilimumab groups, re-
spectively. At the current database lock, most 
patients were no longer receiving trial therapy, 
and 36 patients were continuing the trial treat-
ment (12 in the nivolumab-plus-ipilimumab group 
and 24 in the nivolumab group).
Survival Outcomes
Overall survival was longer in the two nivolumab-
containing groups than in the ipilimumab group. 
The median overall survival was more than 60.0 
months (median not reached; 95% confidence 
interval [CI], 38.2 to not reached) in the nivolum-
ab-plus-ipilimumab group, 36.9 months (95% CI, 
28.2 to 58.7) in the nivolumab group, and 19.9 
months (95% CI, 16.8 to 24.6) in the ipilimumab 
group (Fig. 1A). Overall survival at 5 years was 
52% in the nivolumab-plus-ipilimumab group 
and 44% in the nivolumab group, as compared 
with 26% in the ipilimumab group.
The median progression-free survival was 
11.5 months (95% CI, 8.7 to 19.3) in the nivolumab-
plus-ipilimumab group, 6.9 months (95% CI, 5.1 
to 10.2) in the nivolumab group, and 2.9 months 
(95% CI, 2.8 to 3.2) in the ipilimumab group 
(Fig. 1B). Five-year progression-free survival was 
36%, 29%, and 8% in the nivolumab-plus-ipilim-
umab, nivolumab, and ipilimumab groups, re-
spectively.
Overall survival and progression-free survival 
were also evaluated in patient subgroups (Fig. S2). 
Among patients with tumors with BRAF mutations 
and those with tumors without BRAF mutations, 
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Figure 1. Kaplan–Meier Estimates of Survival in the Overall Population.
Patients were followed for a minimum of 60 months (dashed line). Symbols (tick marks, triangles, and circles) indicate censored data. 
Panel A shows the Kaplan–Meier estimates of overall survival. The median overall survival was longer than 60.0 months (95% confidence 
interval [CI], 38.2 to not reached) in the nivolumab‑plus‑ipilimumab group, 36.9 months (95% CI, 28.2 to 58.7) in the nivolumab group, 
and 19.9 months (95% CI, 16.8 to 24.6) in the ipilimumab group. The hazard ratio for death was 0.52 (95% CI, 0.42 to 0.64; P<0.001) for 
nivolumab plus ipilimumab versus ipilimumab, 0.63 (95% CI, 0.52 to 0.76; P<0.001) for nivolumab versus ipilimumab, and 0.83 (95% CI, 
0.67 to 1.03) for nivolumab plus ipilimumab versus nivolumab. Overall survival at 5 years was 52% in the nivolumab‑plus‑ipilimumab 
group, 44% in the nivolumab group, and 26% in the ipilimumab group. Panel B shows the Kaplan–Meier estimates of progression‑free 
survival as assessed by the investigator. The median progression‑free survival was 11.5 months (95% CI, 8.7 to 19.3) in the nivolumab‑
plus‑ipilimumab group, 6.9 months (95% CI, 5.1 to 10.2) in the nivolumab group, and 2.9 months (95% CI, 2.8 to 3.2) in the ipilimumab 
group. The hazard ratio for disease progression or death was 0.42 (95% CI, 0.35 to 0.51; P<0.001) for nivolumab plus ipilimumab versus 
ipilimumab, 0.53 (95% CI, 0.44 to 0.64; P<0.001) for nivolumab versus ipilimumab, and 0.79 (95% CI, 0.64 to 0.96) for nivolumab plus 
ipilimumab versus nivolumab. Progression‑free survival at 5 years was 36% in the nivolumab‑plus‑ipilimumab group, 29% in the nivolu‑
mab group, and 8% in the ipilimumab group.
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overall survival at 5 years was 60% and 48%, 
respectively, in the nivolumab-plus-ipilimumab 
group; 46% and 43% in the nivolumab group; and 
30% and 25% in the ipilimumab group (Fig. 2). 
Five-year overall survival among patients with 
normal lactate dehydrogenase levels was 60%, 
53%, and 34% in the nivolumab-plus-ipilimumab, 
nivolumab, and ipilimumab groups, respectively; 
among patients with elevated lactate dehydroge-
nase levels, these rates were 38%, 28%, and 15% 
(Fig. S3). Tumor PD-L1 expression alone was not 
predictive of efficacy outcomes (Figs. S4 and S5 
and Table S3); this finding was consistent with 
previous results.4
Response
The rate of objective response among patients 
who were receiving trial therapy was 58% in the 
nivolumab-plus-ipilimumab group, 45% in the 
nivolumab group, and 19% in the ipilimumab 
group (Table 1). The rate of complete response 
was 22%, 19%, and 6%, respectively; all these 
rates of complete response had increased since 
the previous analysis.4 At database lock, the me-
dian duration of response had not been reached 
in the nivolumab-plus-ipilimumab and nivolumab 
groups and was 14.4 months in the ipilimumab 
group, with ongoing responses at 5 years in 62%, 
61%, and 40% of the patients with a response, 
respectively. The duration of response was sus-
tained across stratification subgroups (accord-
ing to BRAF mutation status, PD-L1 status, and 
metastasis stage).
Outcomes after Treatment
As a part of the subsequent therapy received by 
patients for the management of progressive dis-
ease, 21%, 29%, and 40% of patients who were 
randomly assigned to nivolumab plus ipilimu-
mab, nivolumab, and ipilimumab, respectively, 
received radiotherapy and 21%, 23%, and 30% 
underwent surgery. A total of 46%, 59%, and 75% 
of all patients who were randomly assigned to 
nivolumab plus ipilimumab, nivolumab, and ipilim-
umab, respectively, received subsequent systemic 
therapy (Table S4). Excluding patients who died 
and had not received subsequent therapy, the 
median time from randomization to subsequent 
systemic therapy was more than 60.0 months (me-
dian not reached) in the nivolumab-plus-ipilim-
umab group, 25.2 months in the nivolumab 
group, and 8.0 months in the ipilimumab group.
The assessment of the treatment-free interval 
from the last dose of the trial drug to subse-
quent systemic therapy or to the last known date 
alive excluded patients who discontinued trial 
follow-up or died before receiving subsequent 
systemic therapy. The median treatment-free in-
terval was 18.1 months in the nivolumab-plus-
ipilimumab group, 1.8 months in the nivolumab 
group, and 1.9 months in the ipilimumab group 
(Fig. 3A). In addition, of the patients who were 
alive at the time of the current analysis, the per-
centage who were not receiving trial treatment 
or subsequent systemic therapy was 74% in the 
nivolumab-plus-ipilimumab group, 58% in the 
nivolumab group, and 45% in the ipilimumab 
group (Fig. 3B). Survival outcomes at 5 years of 
follow-up were similar between patients who 
discontinued nivolumab plus ipilimumab be-
cause of treatment-related adverse events during 
the induction phase (Fig. S6) and the overall 
population (Fig. 1).
Safety
As expected in this long-term follow-up, the re-
sults of safety analyses (Tables S5 through S7) 
were similar to the previously reported results.4 
Grade 3 or 4 treatment-related adverse events 
occurred in 59%, 23%, and 28% of the patients 
in the nivolumab-plus-ipilimumab, nivolumab, 
and ipilimumab groups, respectively. The medi-
an time to resolution of treatment-related select 
adverse events in the various categories was 
generally less than 12 weeks, with the exception 
of skin-related adverse events in patients who 
received nivolumab, which resolved by a median 
of 40.6 weeks, and some events that had not yet 
resolved (primarily endocrine events, for which 
long-term hormonal therapy may be warranted). 
All treatment-related select adverse events that 
were unresolved at the time of the current analy-
sis (regardless of time of onset) are listed in 
Table S8. In addition, no new deaths that were 
considered by the investigator to be related to a 
trial drug were reported (Table S9).3,4 No previ-
ously unreported long-term toxic effects were 
noted.
Health-Related Quality of Life
The EQ-5D-3L standardized instrument was 
used to investigate health-related quality of life 
in the three treatment groups. Baseline rates of 
EQ-5D-3L completion were similar among the 
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treatment groups and ranged from 88% to 92% 
(Table S10). As would be expected from rates of 
discontinuation of the trial treatment over time,2,3 
fewer than 10% of patients who underwent ran-
domization were included in the assessment of 
health-related quality of life while receiving 
treatment after 3 years of trial follow-up; how-
ever, these patients continued to be followed for 
survival and would have been included in post-
treatment assessments of health-related quality 
of life (after disease progression or discontinua-
tion of the trial treatment).
According to published estimates for the EQ-
5D-3L,11 a change in quality of life was consid-
ered to be clinically meaningful if the mean 
changes from baseline in the index score were 
above (better) or below (worse) the bounds of 
0.08.10,11 For the duration of treatment, time after 
discontinuation of treatment for any reason, and 
the treatment-free interval, changes in the index 
score were generally within the 0.08 boundary in 
patients in the nivolumab-plus-ipilimumab and 
nivolumab treatment groups, indicating no mean-
ingful sustained deterioration of health-related 
quality of life (Fig. S7). During follow-up for sur-
vival, deterioration outside the 0.08 boundary 
occurred more frequently in the ipilimumab mono-
therapy group than in the other treatment groups.
Discussion
Historically, 5-year survival rates among patients 
with metastatic melanoma were dismal. Advances 
in basic science have produced meaningful thera-
peutic interventions for this disease in the areas 
of targeted oncogenic pathway inhibition and 
immune modulation. The current results of the 
CheckMate 067 trial set a new foundation on 
which to make improvements in long-term effi-
cacy outcomes with the combination of nivolumab 
plus ipilimumab.
At 3 years after treatment initiation, a plateau 
on the survival curve was evident in the groups 
that received regimens containing nivolumab.3,4 
The apparent plateau with nivolumab plus ipilim-
umab has continued with longer follow-up; this 
indicates sustained long-term survival in ap-
proximately half the population of patients who 
received nivolumab plus ipilimumab, taking into 
account that subsequent therapies also had an 
effect on survival outcomes. Nivolumab plus 
ipilimumab is also currently the only treatment 
for metastatic melanoma for which median over-
all survival has not been reached at 5 years. In 
addition, complete response rates among patients 
receiving trial therapy have steadily increased 
across all groups since the original analysis2; this 
indicates that the best response can improve over 
time with immune checkpoint inhibitors. The 
treatment-free interval continued to lengthen in 
the nivolumab-plus-ipilimumab group, and the 
percentage of patients who were alive and not 
receiving treatment continued to increase across 
the groups. No new safety signals were observed, 
and no meaningful, sustained deterioration (i.e., 
limited fluctuations outside the 0.08 boundary) 
of health-related quality of life was observed dur-
ing treatment or after discontinuation of treatment 
in the nivolumab-plus-ipilimumab and nivolumab 
monotherapy groups, although health-related 
quality of life deteriorated after discontinuation 
of ipilimumab.
This analysis from the CheckMate 067 trial 
showed that nivolumab-containing regimens were 
associated with a benefit with respect to overall 
survival and progression-free survival across pa-
tient subgroups. In addition, the analysis con-
firmed improved long-term clinical outcomes 
Figure 2 (facing page). Kaplan–Meier Estimates  
of Overall Survival and Progression-free Survival 
among Patients with or without BRAF Mutations.
Patients were followed for a minimum of 60 months 
(dashed lines). Symbols (tick marks, triangles, and cir‑
cles) indicate censored data. The median overall sur‑
vival among patients with BRAF mutations was longer 
than 60.0 months (95% CI, 50.7 to not reached) in the 
nivolumab‑plus‑ipilimumab group, 45.5 months (95% 
CI, 26.4 to not reached) in the nivolumab group, and 
24.6 months (95% CI, 17.9 to 31.0) in the ipilimumab 
group (Panel A). The median overall survival among 
patients without BRAF mutations was 39.1 months 
(95% CI, 27.5 to not reached) in the nivolumab‑plus‑
ipilimumab group, 34.4 months (95% CI, 24.1 to 59.2) 
in the nivolumab group, and 18.5 months (95% CI, 
14.1 to 22.7) in the ipilimumab group (Panel B). The 
median progression‑free survival among patients with 
BRAF mutations was 16.8 months (95% CI, 8.3 to 
32.0) in the nivolumab‑plus‑ipilimumab group, 5.6 
months (95% CI, 2.8 to 9.5) in the nivolumab group, 
and 3.4 months (95% CI, 2.8 to 5.2) in the ipilimumab 
group (Panel C). The median progression‑free survival 
among patients without BRAF mutations was 11.2 
months (95% CI, 7.0 to 18.1) in the nivolumab‑plus‑
ipilimumab group, 8.2 months (95% CI, 5.1 to 19.6) in 
the nivolumab group, and 2.8 months (95% CI, 2.8 to 
3.1) in the ipilimumab group (Panel D).
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with nivolumab plus ipilimumab (median overall 
survival, >60.0 months [median not reached]; 
5-year overall survival, 60%) and nivolumab (me-
dian overall survival, 45.5 months; 5-year overall 
survival, 46%), as compared with ipilimumab, 
among patients with tumors with BRAF mutations. 
Variable
Nivolumab plus 
Ipilimumab 
(N = 314)
Nivolumab 
(N = 316)
Ipilimumab 
(N = 315)
Best overall response — no. (%)†
Complete response  69 (22)  60 (19) 18 (6)
Partial response 114 (36)  81 (26)  42 (13)
Stable disease  38 (12) 30 (9)  69 (22)
Progressive disease  74 (24) 121 (38) 159 (50)
Unable to determine 19 (6) 24 (8) 27 (9)
Objective response‡
Patients with response
No. 183 141 60
% (95% CI) 58 (53−64) 45 (39−50) 19 (15−24)
Estimated odds ratio (95% CI)§ 6.35 (4.38−9.22) 3.54 (2.46−5.10) —
P value§ <0.001 <0.001 —
Median duration of response (95% CI) — mo
Intention‑to‑treat population NR¶ NR (50.4−NR) 14.4 (8.3−53.6)
BRAF mutation status
Patients with BRAF mutations NR (21.0−NR) 55.0 (20.6−NR) 14.4 (6.9−NR)
Patients without BRAF mutations NR (42.4−NR) NR (50.4−NR) 19.2 (6.0−56.4)
Metastasis stage
M10/M1a/M1b NR (NR−NR) NR (36.3−NR) 13.4 (6.0−31.3)
M1c NR (15.8− NR) NR (26.2−NR) 47.4 (5.1−NR)
PD‑L1 expression level
<5% NR (40.1−NR) NR (50.4−NR) 12.8 (5.3−53.6)
≥5% NR (18.1−NR) NR (26.7−NR) 31.3 (6.1−NR)
Lactate dehydrogenase level
≤ULN NR (44.0−NR) NR (45.7−NR) 22.3 (6.9−56.4)
>ULN NR (25.4−NR) NR (13.8−NR) 11.6 (1.8−NR)
Patients with complete response NR (NR−NR) NR (NR−NR) NR (13.3−NR)
Continued response — no. of patients/
total no. (%)
57/69 (83) 49/60 (82) 13/18 (72)
Patients with partial response 19.8 (10.2−NR) 25.1 (16.4−NR) 8.3 (4.2−14.4)
Continued response — no. of patients/
total no. (%)
56/114 (49) 37/81 (46) 11/42 (26)
*  NR denotes not reached, PD‑L1 programmed cell death ligand 1, and ULN upper limit of the normal range.
†  The best overall response was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
‡  Data included patients with a complete response and those with a partial response. The calculation of the 95% confi‑
dence interval was based on the Clopper–Pearson method.
§  The comparison is with the ipilimumab group.
¶  Although a median was reported in the previous analysis,4 the estimate was immature and greater than the minimum 
trial follow‑up.
Table 1. Response to Treatment.*
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The results of a pooled analysis of two phase 3 
trials of combined BRAF and MEK inhibition 
with dabrafenib plus trametinib in patients with 
advanced melanoma and BRAF mutations were 
also reported recently. Those results showed a 
median overall survival of 25.9 months (95% CI, 
22.6 to 31.5) and a 5-year overall survival of 34% 
(95% CI, 30 to 38).12 Comparisons between stud-
ies of BRAF inhibitors and immune checkpoint 
inhibitors are not robust because of the many 
differences in the trial populations. Overall sur-
vival outcomes in the current analysis were also 
favorable for nivolumab plus ipilimumab and 
nivolumab in patients with normal lactate dehy-
drogenase levels and in those with elevated lac-
tate dehydrogenase levels.
Consistent with previous analyses,2-4 both 
treatments (the nivolumab-plus-ipilimumab com-
bination and nivolumab monotherapy) led to 
better objective response rates, progression-free 
survival, and overall survival than ipilimumab, 
regardless of PD-L1 expression. However, the 
variations in efficacy results across PD-L1 cutoff 
values combined with the analysis of the diag-
nostic usefulness of PD-L1 (i.e., the time-depen-
dent receiver-operating-characteristic analysis) sug-
gest that tumor PD-L1 expression alone is a poor 
predictive marker of efficacy outcomes in this 
population, as reported previously.3,4
No new safety signals or additional treat-
ment-related deaths were noted at this 5-year 
18.1 (0.0−65.1)
1.8 (0.0−62.5)
1.9 (0.1−64.7)
Nivolumab
plus
Ipilimumab
(N=220)
Nivolumab
(N=226)
Ipilimumab
(N=235)
0 2 6 8 10 12
Months
B Patients Alive at 5-Yr Data Cutoff
A Median Treatment-free Interval
4 14 16 18 20
Nivolumab plus Ipilimumab (N=151)
Median follow-up, 63.5 mo
(range, 56.9−68.7)
8%
(N=12)
74%
(N=112)
18%
(N=27)
Nivolumab (N=130)
Median follow-up, 63.5 mo
(range, 54.6–67.9)
58%
(N=75)
18%
(N=24)
24%
(N=31)
Ipilimumab (N=67)
Median follow-up, 63.3 mo
(range, 57.0–67.7)
45%
(N=30)
55%
(N=37)
Subsequent systemic therapy No treatmentTrial therapy
Figure 3. Analyses of the Treatment-free Interval  
and Outcomes after Treatment.
Panel A shows the median treatment‑free interval in 
each treatment group. Among 313 patients who re‑
ceived treatment in the nivolumab‑plus‑ipilimumab 
group, 220 patients were included in the analysis of 
the treatment‑free interval and 93 were excluded  
(12 were still receiving trial treatment, 53 had died  
and never received subsequent systemic therapy, and 
28 were no longer in follow‑up and had never received 
subsequent therapy). Among 313 patients who re‑
ceived treatment in the nivolumab group, 226 patients 
were included and 87 were excluded (24 were still re‑
ceiving trial treatment, 45 had died and never received 
subsequent systemic therapy, and 18 were no longer 
in follow‑up and had never received subsequent thera‑
py). Among 311 treated patients in the ipilimumab 
group, 235 patients were included and 76 were exclud‑
ed (57 had died and never received subsequent sys‑
temic therapy, and 19 were no longer in follow‑up and 
had never received subsequent therapy). The duration 
of treatment was 3.6 months (range, 0.0 to 57.0) in the 
nivolumab‑plus‑ipilimumab group, 7.6 months (range, 
0.0 to 62.9) in the nivolumab group, and 3.7 months 
(range, 0.0 to 49.9) in the ipilimumab group. Panel B 
shows the percentage of patients alive at the 5‑year 
data cutoff date who were still receiving trial therapy, 
who were receiving subsequent systemic therapy, or 
who were not receiving trial therapy and had never re‑
ceived subsequent systemic therapy (no treatment).
n engl j med 381;16 nejm.org October 17, 20191544
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
follow-up. As reported previously,4 the incidences 
of treatment-related adverse events and treatment-
related discontinuation of therapy were higher 
with nivolumab plus ipilimumab than with either 
nivolumab or ipilimumab alone. However, over-
all survival and progression-free survival among 
patients who discontinued nivolumab plus ipilim-
umab because of a treatment-related adverse 
event during the induction phase were similar to 
the respective survival rates in the overall popu-
lation; this indicates that early discontinuation 
due to an adverse event does not negatively affect 
long-term survival among these patients. The ma-
jority of treatment-related adverse events leading 
to discontinuation of nivolumab plus ipilimumab 
occurred early in treatment2-4; however, given the 
adoption of checkpoint blockade therapy, long-
term follow-up of patients for the appearance of 
late-onset toxic effects is critical. In addition, stud-
ies of alternative dosing regimens involving pa-
tients with advanced melanoma are under way13; 
these studies may help to inform the safety 
profile of nivolumab plus ipilimumab and may 
also affect global value.
The evaluation of quality of life in patients 
receiving therapy for melanoma is also an im-
portant factor for both physicians and patients 
to consider. The EQ-5D-3L results from this 
5-year analysis showed no sustained deterioration 
in health-related quality of life in the nivolumab-
plus-ipilimumab or nivolumab monotherapy groups 
during or after treatment; these findings are con-
sistent with those of previous analyses.14 However, 
clinically meaningful deterioration was observed 
more frequently in the ipilimumab group than in 
the groups receiving nivolumab.
In conclusion, sustained long-term overall sur-
vival at 5 years was observed in a greater percent-
age of patients with advanced melanoma who 
received nivolumab plus ipilimumab or nivolumab 
alone than of those who received ipilimumab 
alone.
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